Any current/future new fundraising through debt or equity?

There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript. The company is focused on organic expansion by adding 12 to 15 new centers annually and is exploring inorganic growth through strategic partnerships and acquisitions. Capex guidance is around INR 70 crores per year for expansion and maintenance; this does not include acquisitions. The company is actively looking for acquisitions and partnerships but no specifics on funding methods (debt or equity) for these are mentioned. Lease liabilities are clarified under accounting standards

Any current/future capex/capital investment/strategic investment?

Suraksha Diagnostic Limited has budgeted a capital expenditure (capex) of around INR 70 crores per year. Of this capex, 5% to 7% is allocated towards maintenance, with the remainder directed towards expansion. The company plans to add 12 to 15 new centers annually over the next three years, targeting a total of 100 centers within that period. Future capex plans do not include potential mergers and acquisitions (M&A); acquisitions will be additional to the INR 70 crore capex. The company is actively exploring strategic partnerships and acquisitions that align with their values to expand geograp

Future growth expectations in sales/revenue/volumes?

Targeting a revenue growth of 15% annually, as confirmed by management. Volume mix expected to remain stable with around 75% pathology and 25% radiology tests. Continued organic expansion with plans to open 12-15 new centers every year for the next 3 years, aiming to reach 100 centers. Focus on increasing the number of polyclinic chambers and associated doctor fees, showing improved conversion rates. Stable revenue mix between pathology (around 54-56%) and radiology (44-45%), consistent over the last 2-3 years. Growth supported by technology investments and operational efficiencies. Green shoo

Future growth expectations in earnings/operating earnings/profits/EPS?

Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management. The company plans a 100 basis points (1%) expansion in EBITDA margin each year. EBITDA margins for existing centers are targeted around 40-41% over the next 2-3 years. New centers, including small and medium ones, typically become EBITDA positive within 3-4 months; larger centers take 6-7 months. The company is focusing on opening 12-15 new centers annually over the next 3 years to reach 100 centers. Operating leverage and cost control measures contributed to a 16.7% YoY EBITDA increase in Q3 FY25

IN US

Sale is live|00:00:00left today

Suraksha Diagnostic LtdQ4 FY26Healthcare Services

Suraksha Diagnostic Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹274P/E: 47.8Market Cap: ₹1.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Targeting a revenue growth of 15% annually, as confirmed by management.
→Volume mix expected to remain stable with around 75% pathology and 25% radiology tests.
→Continued organic expansion with plans to open 12-15 new centers every year for the next 3 years, aiming to reach 100 centers.
→Focus on increasing the number of polyclinic chambers and associated doctor fees, showing improved conversion rates.
→Stable revenue mix between pathology (around 54-56%) and radiology (44-45%), consistent over the last 2-3 years.
→Growth supported by technology investments and operational efficiencies.
→Green shoots observed in accommodating hospital chains' super specialists in polyclinics.
→Expect volume growth from specialized pathology tests, currently at ~45%, with an aim to increase their share over the coming years.

Margin guidance

Category 1

→Suraksha Diagnostic aims for a revenue growth target of 15% annually as reaffirmed by management.
→The company plans a 100 basis points (1%) expansion in EBITDA margin each year.
→EBITDA margins for existing centers are targeted around 40-41% over the next 2-3 years.
→New centers, including small and medium ones, typically become EBITDA positive within 3-4 months; larger centers take 6-7 months.
→The company is focusing on opening 12-15 new centers annually over the next 3 years to reach 100 centers.
→Operating leverage and cost control measures contributed to a 16.7% YoY EBITDA increase in Q3 FY25 and 22.4% over 9 months FY25.
→Profit after tax grew by approximately 31.9% YoY in Q3 FY25.
→Guidance explicitly stays on track despite short-term impacts like doctor strikes and seasonality.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company is focused on organic expansion by adding 12 to 15 new centers annually and is exploring inorganic growth through strategic partnerships and acquisitions.
→Capex guidance is around INR 70 crores per year for expansion and maintenance; this does not include acquisitions.
→The company is actively looking for acquisitions and partnerships but no specifics on funding methods (debt or equity) for these are mentioned.
→Lease liabilities are clarified under accounting standards and are not considered traditional debt.
→Overall, no explicit plans for fundraising through debt or equity were stated in this conference call.

Order book

The transcript from the Suraksha Diagnostic Limited Q3 & 9M FY25 Earnings Call does not explicitly mention details about the current or expected order book or pending orders. However, some relevant insights related to business growth and expansion plans include: - The company is focused on expanding its diagnostic center network with plans to add 12 to 15 new centers each year. - As of December 2024, Suraksha had 53 diagnostic centers, with additional centers opening in January 2025 and more planned by March 2025. - There is ongoing exploration of inorganic growth via strategic partnerships and acquisitions aligned with their long-term vision. - The company is increasing capacity and services, including adding super specialists in polyclinics. - New technologies have been introduced, positioning Suraksha as the largest genomics platform in the East with expansion of the B2B segment. No direct mention of a quantified order book or pending orders was provided in the transcript.

Capex plans

Yes

→Suraksha Diagnostic Limited has budgeted a capital expenditure (capex) of around INR 70 crores per year.
→Of this capex, 5% to 7% is allocated towards maintenance, with the remainder directed towards expansion.
→The company plans to add 12 to 15 new centers annually over the next three years, targeting a total of 100 centers within that period.
→Future capex plans do not include potential mergers and acquisitions (M&A); acquisitions will be additional to the INR 70 crore capex.
→The company is actively exploring strategic partnerships and acquisitions that align with their values to expand geographic footprint and service offerings.
→Investments include technology upgrades, such as adding new technologies to reference labs (e.g., microarray, standard sequencing) to strengthen genomics capabilities.
→Plans also include opening polyclinic chambers and expansion in PPP models as part of strategic growth.

How does Suraksha Diagnostic Ltd rank vs peers in Healthcare Services?

Pro feature

1Suraksha Diagnostic Ltd

Rev 3Mar 1

See full Healthcare Services sector rankings

Want more stocks like Suraksha Diagnostic Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio